CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ev3 Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ev3 Inc.
3033 Campus Drive
5th Floor
Phone: (763) 398-7000p:763 398-7000 Plymouth, MN  55441  United States Ticker: EVVVEVVV
This company was Merged or Acquired on 1/26/2015.
This company ceased filing statements with the SEC on 7/22/2010.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
ev3 Inc. (ev3) is a global endovascular company focused on identifying and treating peripheral vascular disease, including, in particular, lower extremity arterial disease and neurovascular disease. It operates through two business segments: peripheral vascular and neurovascular. Its product portfolio includes a spectrum of over 100 products consisting of over 1,500 stock keeping units (SKUs), including plaque excision, stents, embolic protection and thrombectomy devices, carotid stenting solutions, percutaneous transluminal angioplasty (PTA) balloons and other procedural support products for the peripheral vascular market, and embolic coils, flow diversion and flow restoration devices, liquid embolics, flow directed and other micro catheters, occlusion balloon systems, guidewires, neuro stents and retrieval devices for the neurovascular market. On June 23, 2009, it acquired Chestnut Medical Technologies, Inc. In July 2010, Covidien plc acquired the Company.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
4/4/201012/31/2009YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Daniel J.Levangie 59 4/6/2008 2/23/2007
President, Chief Executive Officer, Director Robert J.Palmisano 65 4/1/2008 4/1/2008
Chief Financial Officer, Senior Vice President ShawnMcCormick 45 1/19/2009 1/19/2009
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Chestnut Medical Technologies, Inc.
Dendron GmbH
ev3 Australia Pty Limited
21 additional Business Names available in full report.

General Information
Number of Employees: 1,350 (As of 12/31/2009)
Outstanding Shares: 113,181,212 (As of 4/28/2010)
Shareholders: 188
Stock Exchange: NASD
Federal Tax Id: 320138874
Fax Number: (763) 398-7200


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023